Protalix BioTherapeutics, Inc. Common Stock (PLX) — Analysis Summary
Protalix BioTherapeutics, Inc. Common Stock (PLX) has a market cap of $192.57M with year-over-year revenue growth of -1.2%. Net margin stands at -12.5%. The stock trades at a P/E ratio of 12.6.
Key Takeaways
- Revenue changed -1.2% year-over-year
- Net margin of -12.5%
- P/E ratio of 12.6
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, PLX posted revenue growth of -1.2% and trades at a P/E of 12.6.
Protalix BioTherapeutics, Inc. Common Stock (PLX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
226
Headquarters
HACKENSACK, NJ
Exchange
XASE
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.